molecular Diagnostic testing in Non-small Cell Lung Cancer

Introduction Over the past decade, the oncology community has witnessed a revolution in our understanding of the biology of lung cancer with the identification of a significant proportion of patients whose tumors harbor targetable molecular changes. these recurrent genomic alterations include mutations, gene rearrangements, and copy number changes in relevant lung cancer genes (Figure 1). A variety of diagnostic assays can be used to identify these abnormalities, which act as predictive biomarkers of benefit from a corresponding targeted therapy. this review summarizes the current state of knowledge regarding molecular drivers in lung cancer, available platforms to diagnose these genomic alterations, and factors affecting the choice and interpretation of diagnostic assays.